Positive News Sentiment NASDAQ:ADIL Adial Pharmaceuticals - ADIL Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Adial Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.35 -0.03 (-7.85%) (As of 03/24/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.35▼$0.4050-Day Range$0.31▼$0.5652-Week Range$0.20▼$2.27Volume167,638 shsAverage Volume1.65 million shsMarket Capitalization$10.04 millionP/E RatioN/ADividend YieldN/APrice Target$3.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Adial Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside751.8% Upside$3.00 Price TargetShort InterestHealthy1.34% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.69Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.56) to ($0.70) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.95 out of 5 starsMedical Sector617th out of 1,005 stocksPharmaceutical Preparations Industry293rd out of 486 stocks 3.3 Analyst's Opinion Consensus RatingAdial Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.00, Adial Pharmaceuticals has a forecasted upside of 751.8% from its current price of $0.35.Amount of Analyst CoverageAdial Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.34% of the outstanding shares of Adial Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverAdial Pharmaceuticals has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Adial Pharmaceuticals has recently increased by 37.91%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAdial Pharmaceuticals does not currently pay a dividend.Dividend GrowthAdial Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ADIL. Previous Next 3.2 News and Social Media Coverage News SentimentAdial Pharmaceuticals has a news sentiment score of 1.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Adial Pharmaceuticals this week, compared to 0 articles on an average week.Search InterestOnly 7 people have searched for ADIL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Adial Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Adial Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders21.22% of the stock of Adial Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 7.42% of the stock of Adial Pharmaceuticals is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Adial Pharmaceuticals are expected to decrease in the coming year, from ($0.56) to ($0.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Adial Pharmaceuticals is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adial Pharmaceuticals is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdial Pharmaceuticals has a P/B Ratio of 2.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Adial Pharmaceuticals (NASDAQ:ADIL) StockAdial Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the treatment of alcohol use disorder. Its lead product is AD04, a selective serotonin-3 antagonist. The company was founded by Bankole A. Johnson in November 2010 and is headquartered in Charlottesville, VA.Read More Receive ADIL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adial Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ADIL Stock News HeadlinesMarch 21, 2023 | finance.yahoo.comAdial Pharmaceuticals Engages The Keswick Group to Advance Partnering Activities for the Clinical Development of AD04 for Alcohol Use DisorderMarch 8, 2023 | finance.yahoo.comAdial Pharmaceuticals to Present at the 35th Annual Roth Conference on March 14thMarch 26, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.March 8, 2023 | finance.yahoo.comAdial Pharmaceuticals to Present at the 35th Annual Roth Conference on March 14thMarch 7, 2023 | msn.comADIL Soars after Positive Regulatory UpdateMarch 6, 2023 | markets.businessinsider.comAdial Pharma Surges 80% On Update Of AD04March 6, 2023 | finance.yahoo.comAdial Pharmaceuticals Provides Update on Regulatory Strategy for AD04 for Treatment of Alcohol Use DisorderMarch 2, 2023 | finance.yahoo.comAdial Pharmaceuticals Schedules Business Update Conference CallMarch 26, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.February 28, 2023 | finance.yahoo.comAdial Pharmaceuticals, Inc. (NASDAQ:ADIL): Is Breakeven Near?February 27, 2023 | finance.yahoo.comAdial Pharmaceuticals Announces Closing of $0.75 Million At-The-Market Registered Direct OfferingFebruary 24, 2023 | finance.yahoo.comAdial Pharmaceuticals Announces Pricing of $0.75 Million At-The-Market Registered Direct OfferingFebruary 21, 2023 | finance.yahoo.comAdial Pharmaceuticals Confirms Scheduling of Meetings with FDA and European Regulatory Agencies to Advance Clinical Development of AD04 for Alcohol Use DisorderFebruary 1, 2023 | finance.yahoo.comAdial Pharmaceuticals Enters Into Option Agreement for Sale of Purnovate Assets to AdenomedNovember 16, 2022 | seekingalpha.comAdial Pharmaceuticals GAAP EPS of -$0.12 beats by $0.06October 4, 2022 | finance.yahoo.comAdial Pharma Touts Positive Preclinical Data From Chronic Pain CandidateSeptember 28, 2022 | benzinga.comAdial Pharmaceuticals Announces Positive In Vivo Data for Purnovate's PNV-5030 as a Potential Treatment for Chronic PainSeptember 26, 2022 | finance.yahoo.comAdial Pharmaceuticals Announces Positive In Vivo Data for Purnovate’s PNV-5030 as a Potential Treatment for Chronic PainSeptember 26, 2022 | finance.yahoo.comAdial Pharmaceuticals Announces Positive In Vivo Data for Purnovate’s PNV-5030 as a Potential Treatment for Chronic PainSeptember 22, 2022 | seekingalpha.comADIL Adial Pharmaceuticals, Inc.September 6, 2022 | nasdaq.comAdial Pharma Says Purnovate's PNV-6005 Reports Positive Data In Treating Ulcerative ColitisSeptember 6, 2022 | finance.yahoo.comAdial Pharma's Subsidiary Shows Encouraging Preclinical Action For Inflammatory Bowel Disease CandidateSeptember 6, 2022 | finance.yahoo.comAdial Pharmaceuticals Announces Positive In-Vivo Non-clinical Data with Purnovate’s PNV-6005 as a Potential Treatment for Ulcerative ColitisSeptember 1, 2022 | finance.yahoo.comHere's Why Adial Pharmaceuticals, Inc. (ADIL) Could be Great Choice for a Bottom FisherAugust 29, 2022 | finance.yahoo.comZacks.com featured highlights include Eastside Distilling, Adial Pharmaceuticals, The Buckle, Ruth's Hospitality Group and Insight EnterprisesAugust 23, 2022 | seekingalpha.comAdial Clinical Trial: A Fluff Or A Win?August 18, 2022 | uk.investing.comAdial Pharmaceuticals Provides Business Update, Reports Q2See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ADIL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adial Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ADIL Company Calendar Last Earnings8/11/2021Today3/26/2023Next Earnings (Estimated)3/27/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ADIL CUSIPN/A CIK1513525 Webwww.adialpharma.com Phone(434) 422-9800FaxN/AEmployees16Year FoundedN/APrice Target and Rating Average Stock Price Forecast$3.00 High Stock Price Forecast$3.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+751.8%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,420,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-227.60% Return on Assets-156.55% Debt Debt-to-Equity RatioN/A Current Ratio5.10 Quick Ratio5.10 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.17 per share Price / Book2.07Miscellaneous Outstanding Shares28,520,000Free Float22,466,000Market Cap$10.04 million OptionableNot Optionable Beta0.99 Key ExecutivesCary J. ClaibornePresident, Chief Executive Officer & DirectorJoseph TruluckChief Financial Officer, Secretary & TreasurerBankole A. JohnsonChief Medical OfficerJulien DimastromatteoVice President-ResearchAlex LugovoyChief Business OfficerKey CompetitorsLiminal BioSciencesNASDAQ:LMNLPulmatrixNASDAQ:PULMDiffusion PharmaceuticalsNASDAQ:DFFNLandos BiopharmaNASDAQ:LABPAlterity TherapeuticsNASDAQ:ATHEView All CompetitorsInstitutional OwnershipRenaissance Technologies LLCBought 107,656 shares on 2/13/2023Ownership: 0.974%View All Institutional Transactions ADIL Stock - Frequently Asked Questions Should I buy or sell Adial Pharmaceuticals stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Adial Pharmaceuticals in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ADIL shares. View ADIL analyst ratings or view top-rated stocks. What is Adial Pharmaceuticals' stock price forecast for 2023? 2 equities research analysts have issued 12-month price targets for Adial Pharmaceuticals' shares. Their ADIL share price forecasts range from $3.00 to $3.00. On average, they anticipate the company's share price to reach $3.00 in the next year. This suggests a possible upside of 751.8% from the stock's current price. View analysts price targets for ADIL or view top-rated stocks among Wall Street analysts. How have ADIL shares performed in 2023? Adial Pharmaceuticals' stock was trading at $0.2150 at the beginning of the year. Since then, ADIL stock has increased by 63.8% and is now trading at $0.3522. View the best growth stocks for 2023 here. When is Adial Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, March 27th 2023. View our ADIL earnings forecast. How were Adial Pharmaceuticals' earnings last quarter? Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) released its earnings results on Wednesday, August, 11th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by $0.05. What other stocks do shareholders of Adial Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Adial Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Global Partners (GLP), Corbus Pharmaceuticals (CRBP), Aytu BioPharma (AYTU), T2 Biosystems (TTOO), AIM ImmunoTech (AIM), Tandem Diabetes Care (TNDM), vTv Therapeutics (VTVT), Acasti Pharma (ACST) and Adamis Pharmaceuticals (ADMP). When did Adial Pharmaceuticals IPO? (ADIL) raised $8 million in an initial public offering (IPO) on Friday, July 27th 2018. The company issued 1,500,000 shares at a price of $5.00 per share. Joseph Gunnar & Co. served as the underwriter for the IPO and Dawson James Securities was co-manager. What is Adial Pharmaceuticals' stock symbol? Adial Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADIL." Who are Adial Pharmaceuticals' major shareholders? Adial Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (0.97%). Insiders that own company stock include Bankole A Johnson, James W Jr Newman and William B Stilley III. View institutional ownership trends. How do I buy shares of Adial Pharmaceuticals? Shares of ADIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Adial Pharmaceuticals' stock price today? One share of ADIL stock can currently be purchased for approximately $0.35. How much money does Adial Pharmaceuticals make? Adial Pharmaceuticals (NASDAQ:ADIL) has a market capitalization of $10.04 million. The company earns $-19,420,000.00 in net income (profit) each year or ($0.69) on an earnings per share basis. How can I contact Adial Pharmaceuticals? Adial Pharmaceuticals' mailing address is 1180 Seminole Trail Suite 495, Charlottesville VA, 22901. The official website for the company is www.adialpharma.com. The company can be reached via phone at (434) 422-9800 or via email at investor_relations@haynesintl.com. This page (NASDAQ:ADIL) was last updated on 3/26/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.